We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Myovant Sciences Ltd. (“Myovant” or the “Company”) (NYSE: MYOV) in connection with the proposed acquisition of the Company by Sumitovant Biopharma Ltd. and Sumitomo Pharma Co., Ltd.  Under the terms of the merger agreement, the Company’s shareholders will receive $27.00 in cash for each share of Myovant common stock owned.  The transaction is valued at approximately $1.7 billion.

Weiss Law is investigating whether (i) Myovant’s board of directors acted in the best interests of the Company in agreeing to the proposed transaction, (ii) the per-share merger consideration adequately compensates Myovant’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.